摘要
肿瘤坏死因子相关凋亡诱导配体(TRAIL)是近几年研究较热的抗肿瘤新型生物制剂,通过其死亡受体诱导肿瘤细胞凋亡,而对正常细胞无毒性,且与化疗药物具有协同性,但也存在抵抗机制。该文就TRAIL的生物学特点及其受体、TRAIL诱导肿瘤细胞凋亡的机制以及TRAIL在白血病治疗中的进展作一综述。
Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) is a new anti-tumor biological agents which is very hot in recent years through its death receptor-induced apoptosis of tumor cells, and non-toxic to normal cells, and has synergy with the chemotherapy drug,but there is also resistance mechanisms.This article will review the biological characteristics of TRAIL and its receptors,TRAIL-induced apoptosis of tumor cells,as well as the mechanism of TRAIL in leukemia in the progress of treatment.
出处
《国际儿科学杂志》
2010年第2期139-141,共3页
International Journal of Pediatrics